Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children

Infection

Volumn 28, Issue 5, 2000, Pages 287-296

  Nadal, D ^a   Steiner, F ^a   Cheseaux, J J ^b   Wyler Lazarevitch, C A ^c   Aebi, C ^d   Kind, C ^e   Rudin, C ^f  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Children's Hospital   (Switzerland)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e Ostschweizer Children's Hospital   (Switzerland)

^f UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Antiretroviral agents; Children; HIV 1; Nelfinavir; Ritonavir

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PROSPECTIVE STUDY; RASH; SWITZERLAND;

ADOLESCENT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COMPARATIVE STUDY; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMAN; INFANT; MALE; NELFINAVIR; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, MESSENGER; RNA, VIRAL; SUPPORT, NON-U.S. GOV'T;

EID: 0033774311     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s150100070021     Document Type: Article

References (30)

1. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
2. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
3. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma
4. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection
5. HIV type 1 phenotype correlates with the stage of infection in vertically infected children
6. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children
7. Viral load and disease progression in infants infected with the human immunodeficiency virus type 1 N
8. The relationship between serum immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children
9. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants
10. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
11. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
12. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society - USA panel
13. Guidelines for the use of antiretroviral agents in pediatric HIV infection
14. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age
15. Early experience with protease inhibitors in human immunodeficiency virus-infected children
16. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate
17. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children AIDS
18. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: Experience with fifty-four perinatally infected children
19. Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection
20. Protease inhibitor therapy in children with perinatallly acquired HIV infection
21. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 7 disease treated with protease inhibitors
22. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus
23. A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
24. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddl) in children infected with the immundeficiency virus
25. Combination therapy with efavirenz, nelfinavir, and nucleoside-transcriptase inhibitors in children infected with human immunodeficiency virus type 1
26. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
27. Impact of drug resistance mutations on virologic response to salvage therapy
28. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children. A randomized clinical trial
29. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children
30. A preliminary study of ritonavir, a n inhibitor of HIV-1 protease, to treat HIV-1 infection